GlobeNewswire

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/04/2026
MONTREAL and CHARLOTTE, N.C., April 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a [...]
Bionano Announces Publication from Johns Hopkins and MD Anderson Showing that OGM can Outperform Traditional Methods in Analysis of Multiple Myeloma
02/04/2026
SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a study in the American Journal of Hematology demonstrating that optical genome mapping (OGM) can [...]
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer
02/04/2026
REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has [...]
Emergent BioSolutions Participates in Upcoming International Preparedness Conferences
02/04/2026
GAITHERSBURG, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a global life sciences leader with biodefense and medical countermeasures products, announced today that members of its [...]
Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment
02/04/2026
KNOXVILLE, Tenn., April 02, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today highlighted newly published independent preclinical research evaluating the [...]
Burning Rock Announces Founder’s Purchase of Its ADSs
02/04/2026
GUANGZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in [...]
Arch Biopartners Closes Non-Brokered Private Placement
02/04/2026
TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today it has closed a non-brokered private placement offering of 1,000,000 [...]
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
02/04/2026
Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies [...]
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
02/04/2026
Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies [...]
Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
02/04/2026
Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findings Patients in the TED studies demonstrated greater levels of [...]
MyGevity Announces Nationwide Launch of Integrated Health Data Platform
02/04/2026
New system centralizes at-home DNA testing, biological age assessment, and lab diagnostics into a unified reporting experience ST. PETERSBURG, FL, April 02, 2026 (GLOBE NEWSWIRE) -- MyGevity announced the nationwide [...]
Pharming Group announces the filing of its 2025 Annual Report and Form 20-F
02/04/2026
Leiden, the Netherlands, April 2, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced the filing of its Annual Report for the year ended December 31, 2025. [...]
Celldex Announces Pricing of $300 Million Public Offering of Common Stock
02/04/2026
HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 10,345,000 shares of its common [...]
MetaTrim BHB Claims Evaluated: The Quick Burn Keto BHB Formula Everyone is Researching, Meta Trim Ketones
02/04/2026
An informational overview of MetaTrim BHB's keto ketone salt formula, including BHB dosage research context, proprietary blend considerations, pricing structure, and key distinctions between ingredient-level findings [...]
Good oral health isn't complicated — Alberta's dentists want you to know what works
02/04/2026
Simple, proven habits are still the most powerful tools for protecting your health, inside and out EDMONTON, Alberta, April 01, 2026 (GLOBE NEWSWIRE) -- Alberta's dentists have a simple message this Oral Health Month: [...]
Telix Appoints David Gill as Non-Executive Director
02/04/2026
MELBOURNE, Australia and INDIANAPOLIS, April 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the appointment of David Gill as a Non-Executive Director (NED), [...]
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
01/04/2026
In 2025, muzastotug showed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dose cohorts Median overall survival (OS) for the 10 mg/kg cohorts was 19.4 months, with a median [...]
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/04/2026
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib [...]
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01/04/2026
BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on April 1, 2026, the Compensation [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum